ClinicalTrials.gg
CompletedNCT03496207PULSARUpdated Apr 19, 2023Results posted

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)

A Phase 2 interventional study of Placebo and Sotatercept in Pulmonary Arterial Hypertension, sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA. Completed at 43 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-19.

Sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing sotatercept in Pulmonary Arterial Hypertension — 7 open to participants now, 10 under way, 1 of them phase 3. sotatercept · Pulmonary Arterial Hypertension.

Enrollment
7th of 18
106 · median 44
Started
2018
the only one that year
Phase 2
7 of 18
3 open now
Registered
1st of 18
by date
Lead sponsor
5 of 18
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, this one is the 7th largest by enrollment, is the only one that started in 2018, is one of 7 in phase 2, and was the 1st registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

7 of the 18 studies testing sotatercept in Pulmonary Arterial Hypertension are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About sotatercept

sotatercept: first FDA approval 2024 (WINREVAIR), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing sotatercept in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

Study A011-09 is designed to assesses the efficacy and safety of sotatercept (ACE-011) relative to placebo in adults with pulmonary arterial hypertension (PAH). Eligible participants will receive study treatment for 24 weeks during the placebo-controlled treatment period, and then will be eligible to enroll into a 30-month extension period during which all participants will receive sotatercept. All treated patients will also undergo a follow-up period after last study drug treatment.

Read the detailed description

This is a Phase 2, double-blind, randomized, placebo-controlled, parallel-group study of sotatercept plus standard of care (SOC) versus placebo plus SOC in participants with PAH of World Health Organization (WHO) Group 1, functional class II-III. Participants will be randomly assigned in a 3:3:4 ratio to receive placebo, sotatercept 0.3 mg/kg, or sotatercept 0.7 mg/kg by subcutaneous (SC) injection every 21 days for a period of 24 weeks in the placebo-controlled treatment period of the study while on SOC therapy. Evaluations will include changes in pulmonary vascular resistance (PVR), 6-minute walk distance (6MWD), quality of life questionnaires, echocardiographic parameters, and safety. Participants who have not discontinued early from the placebo-controlled treatment period and have had their post-treatment period PVR assessment will be able to continue into the 30-month extension period in which sotatercept-treated participants will receive their latest dose level of sotatercept SC every 21 days and placebo-treated participants will be re-randomized 1:1 to receive sotatercept 0.3 mg/kg SC or sotatercept 0.7 mg/kg SC every 21 days while on SOC therapy.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • PAH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. Documented diagnostic right heart catheterization (RHC) at any time prior to Screening confirming diagnosis of WHO diagnostic pulmonary hypertension Group I: PAH in any of the following subtypes:

    i. Idiopathic ii. Heritable PAH iii. Drug- or toxin-induced PAH iv. PAH associated with connective tissue disease v. PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1 year following shunt repair

  3. Symptomatic pulmonary hypertension classified as WHO functional class II or III
  4. Screening RHC documenting a minimum PVR of ≥400 dyn·sec/cm5 (5 Wood units)
  5. Pulmonary function tests (PFTs) within 6 months prior to Screening as follows:

    1. Total lung capacity (TLC) >70% predicted; or if between 60 to 70% predicted, or not possible to be determined, confirmatory high-resolution computed tomography (CT) indicating no more than mild interstitial lung disease (ILD), per investigator interpretation, or
    2. Forced expiratory volume (first second) ()/ forced vital capacity (FVC) >70% predicted
  6. Ventilation-perfusion (VQ) scan (or, if unavailable a negative CT pulmonary angiogram [CTPA] result, or pulmonary angiography result), any time prior to Screening Visit or conducted during the Screening Period, with normal or low probability result),
  7. No per investigator for RHC during the study
  8. 6MWD ≥150 and ≤550 meters repeated twice at Screening and both values within 15% of each other, calculated from the highest value
  9. PAH therapy at stable (per investigator) dose levels of SOC therapies

Exclusion criteria

Exclusion Criteria:

  1. Stopped receiving any pulmonary hypertension chronic general supportive therapy (e.g, diuretics, oxygen, anticoagulants, digoxin) within 60 days prior to study visit Cycle 1 Day 1 (C1D1)
  2. Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine, vasopressin) within 30 days prior to study visit C1D1
  3. History of atrial septostomy within 180 days prior to Screening
  4. History of more than mild obstructive sleep apnea that is untreated
  5. Known history of portal hypertension or chronic liver disease, including and/or (with evidence of recent infection and/or active virus replication), defined as mild to severe hepatic impairment ( Class A-C)
  6. History of infection-associated PAH
  7. Prior exposure to sotatercept (ACE-011) or luspatercept (ACE-536)
  8. Initiation of an exercise program for cardiopulmonary rehabilitation within 90 days prior to C1D1 or planned initiation during the study (participants who are stable in the maintenance phase of a program and who will continue for the duration of the study are eligible).
  9. Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure (BP) >160 mm Hg or sitting diastolic blood pressure >100 mm Hg during Screening Visit after a period of rest
  10. Systolic BP \<90 mmHg during Screening or at baseline
  11. History of known pericardial constriction
  12. (ECG) with Fridericia's interval (QTcF) >480 msec during Screening Period or C1D1
  13. Personal or family history of long QTc syndrome or sudden cardiac death
  14. Cerebrovascular accident within 3 months of C1D1
  15. History of restrictive or congestive cardiomyopathy
  16. (LVEF) \<45% on historical echocardiogram (ECHO) within 6 months prior to Screening Period (or done as a part of the Screening Period) or pulmonary capillary wedge pressure (PCWP) >15 mmHg as determined in the Screening Period RHC.
  17. Any current or prior history of symptomatic coronary disease (prior myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or cardiac anginal chest pain)
  18. Acutely decompensated heart failure within 30 days prior to study visit C1D1, as per investigator assessment
  19. Significant (≥2+ regurgitation) mitral regurgitation (MR) or aortic regurgitation (AR) valvular disease
  20. Any of the following clinical laboratory values during the Screening Period prior to C1D1:

    1. Baseline >16.0 g/dL
    2. Serum or aspartate aminotransferase levels >3X (ULN) or total >1.5X ULN within 28 days of C1D1
    3. Estimated \<30 ml/min/1.73m2 (4-variable Modification of Diet in Renal Disease equation) within 28 days of C1D1 or required renal replacement therapy within 90 days
    4. WBC count \<4000/mm3
    5. \<100,000/μL
    6. \<1500/mm3
  21. History of opportunistic infection (e.g., invasive candidiasis or pneumocystis pneumonia) within 6 months prior to Screening; serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., septicemia) within 3 months prior to Screening
  22. History of severe allergic or anaphylactic reaction or to recombinant proteins or in the product
  23. Major surgery within 8 weeks prior to C1D1. Participants must have completely recovered from any previous surgery prior to C1D1.
  24. Prior heart or heart-lung transplants or of \<12 month
  25. Pregnant or breastfeeding females
  26. If on , and at any time in the last 30 days prior to the Screening Period: have been receiving doses of >20 mg/day of prednisone (or equivalent) or on a new or changing dose of ≤20 mg/day; only participants receiving stable doses of ≤20 mg prednisone (or equivalent) in last 30 days prior to the Screening Period permitted in the study
  27. History of active , with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in-situ, or ≤2 squamous cell carcinomas of the skin
  28. History of (as determined by the investigator) non-PAH related cardiac, endocrine, hematologic, hepatic, (auto)immune, metabolic, urologic, pulmonary, neurologic, neuromuscular, dermatologic, psychiatric, renal, and/or another disease that may limit participation in the study. diseases are excluded with the exception of those related to PAH etiologies included in this study.
  29. Participation in another clinical trial involving intervention with another investigational drug, approved therapy for investigational use, or investigational device within 4 weeks prior to C1D1, or if the half-life of the previous product is known, within 5 times the half-life prior to C1D1, whichever is longer
  30. Weight >140 kg at Screening
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
106 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive placebo plus SOC by SC injection during the 24-week treatment period. Dosing will occur once every 3 weeks.

    Drug: Placebo · Other: SOC

  • Experimental
    Sotatercept 0.3 mg/kg

    Participants will receive sotatercept 0.3 mg/kg plus SOC by SC injection during the 24-week treatment period. Per protocol, participants may have their doses titrated. Dosing will occur once every 3 weeks.

    Drug: Sotatercept · Other: SOC

  • Experimental
    Sotatercept 0.7 mg/kg

    Participants will receive sotatercept 0.7 mg/kg plus SOC by SC injection during the 24-week treatment period. Per protocol, participants may have their doses titrated. Dosing will occur once every 3 weeks.

    Drug: Sotatercept · Other: SOC

Interventions

  • DrugPlacebo

    Placebo

  • Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.

    Also known as: ACE-011

  • OtherSOC

    SOC therapy refers to approved PAH-specific medications and may consist of monotherapy or combination therapy with endothelin-receptor antagonists, phosphodiesterase 5 (PDE5) inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogues or receptor agonists.

06

What researchers measure

Primary outcomes

  1. Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks

    Each participant's PVR, at resting supine, was measured by right heart catheterization at baseline and at 24 weeks.

    Time frame: Baseline and 24 weeks

  2. Extension Period: Change From Baseline in PVR (Delayed-Start Analysis)

    Each participant's PVR, at resting supine, was measured by right heart catheterization at baseline and the timepoint at which the third right heart catheterization was performed, which occurred between Month 18 and Month 24.

    Time frame: Baseline and timepoint at which third right heart catheterization was performed, which occurred between Month 18 and Month 24

  3. Extension Period: Change From Baseline in PVR (Placebo-Crossed Analysis)

    Each participant's PVR, at resting supine, was measured by right heart catheterization at baseline and the timepoint at which the third right heart catheterization was performed, which occurred between Month 18 and Month 24.

    Time frame: Baseline and the timepoint at which the third right heart catheterization was performed, which occurred between Month 18 and Month 24.

  4. Extension Period: Number of Participants Who Experienced One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

    Time frame: Up to approximately 32 months

  5. Extension Period: Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

    Time frame: Up to 30 months

Secondary outcomes

  1. Base Study: Change From Baseline in 6-Minute Walk Distance (6MWD) at 24 Weeks

    6MWD is measured by an exercise test known as 6-Minute Walk Test (6MWT) that assesses aerobic capacity and endurance. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in performance capacity. Each participant's 6MWD was measured at baseline and at 24 weeks. An increase in the distance walked during the 6MWT indicates improvement in basic mobility.

    Time frame: Baseline and 24 weeks

  2. Base Study: Change From Baseline in Concentration of Amino-Terminal Brain Natriuretic Propeptide (NT-proBNP) at 24 Weeks

    Each participant's laboratory biomarkers N-terminal prohormone brain-type natriuretic peptide (NT-proBNP) or brain-type natriuretic peptide (BNP) were measured at baseline and at 24 weeks.

    Time frame: Baseline and 24 Weeks

  3. Base Study: Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE) at 24 Weeks

    Each participant's TAPSE, which is commonly used to evaluate tricuspid valve annulus movement as an indicator of right heart function, was measured by echocardiography at baseline and 24 weeks.

    Time frame: Baseline and 24 weeks

  4. Base Study: Change From Baseline in Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) Score at Cycle 9

    The CAMPHOR is participant-reported questionnaire that contains 65 items in total, 25 relating to symptoms, 25 relating to quality of life (QoL), and 15 relating to activities. Symptom items are scored from 0-25, with a higher score indicating worse symptoms. QoL items are also scored from 0-25, with a higher score indicating a worse QoL and greater functional limitation. Activity items are scored from 0-30, with a higher score indicating poorer functioning. The combined score is obtained by summing up the symptoms score, QoL score and activity score. The lowest combined score possible is 0, while the highest combined score possible is 80. Each participant's CAMPHOR score was recorded at baseline and on Day 1 of Cycle 9.

    Time frame: Baseline and Day 1 of Cycle 9, up to 24 weeks (Each cycle was 21 days.)

  5. Base Study: Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score

    The SF-36 questionnaire is a participant-reported survey of a participant's health. The survey evaluates 8 aspects of functional health and well-being that relate to either physical health or mental health. The physical component summary is based primarily on physical functioning, bodily pain, and general health. The mental component summary encompasses vitality, social functioning, and emotional and mental health. Total scores for the physical component range from 0-100, with 100 representing the highest level of physical functioning. The total scores for the mental component also range from 0-100, with 100 representing the highest level of mental functioning. Each participant's SF-36 was recorded at baseline and on Day 1 of Cycle 9. Each cycle was 21 days.

    Time frame: Baseline and Day 1 of Cycle 9, up to 24 weeks (Each cycle was 21 days.)

  6. Base Study: Number of Participants Who Experienced Events Indicative of Clinical Worsening of Pulmonary Arterial Hypertension (PAH)

    Events that indicate clinical worsening of PAH include death, need for and/or worsening-related listing for lung and/or heart transplant, need to initiate an approved PAH SOC rescue therapy, PAH-specific hospitalization, or functional deterioration (worsened WHO Functional Class AND 15% decrease in 6MWD).

    Time frame: Up to 24 weeks

  7. Base Study: Number of Participants Who Experienced an Improvement From Baseline in World Health Organization (WHO) Functional Class at 24 Weeks

    The WHO Functional Class describes the severity of a person's pulmonary hypertension symptoms. There are four different classes: I is the mildest and IV the most severe form of pulmonary hypertension.

    Time frame: Baseline and 24 Weeks

  8. Base Study: Number of Participants Who Experienced One or More AEs

    An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

    Time frame: Up to 24 weeks

  9. Base Study: Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

    Time frame: Up to 24 weeks

  10. Base Study: Change From Baseline in Body Mass Index (BMI) at Cycle 9

    Each participant's BMI was measured at baseline and at 24 weeks.

    Time frame: Baseline and Day 1 of Cycle 9, up to 24 weeks (Each cycle was 21 days.)

  11. Base Study: Change From Baseline in Systolic and Diastolic Blood Pressure at Cycle 9

    Each participant's systolic and diastolic blood pressure was taken at baseline and on Day 1 of Cycle 9. Each cycle was 21 days.

    Time frame: Baseline and Day 1 of Cycle 9, up to 24 weeks (Each cycle was 21 days.)

  12. Base Study: Change From Baseline in Respiratory Rate at Cycle 9

    Each participant's respiratory rate (number of breaths per minute) was measured at baseline and on Day 1 of Cycle 9. Each cycle was 21 days.

    Time frame: Baseline and Day 1 of Cycle 9, up to 24 weeks (Each cycle was 21 days.)

  13. Base Study: Change From Baseline in QTcF Interval at Cycle 9

    Each participant's QTcF Interval was measured at baseline and on Day 1 of Cycle 9.

    Time frame: Baseline and Day 1 of Cycle 9, up to 24 weeks (Each cycle was 21 days.)

  14. Base Study: Maximum Plasma Concentration (Cmax) of Sotatercept

    Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Based on population pharmacokinetic (PopPK) modeling of previous sotatercept studies, Cmax occurs at Day 8 of Cycle 1 after a sotatercept dose is given. The sotatercept concentration at Day 8 of Cycle 1 (each cycle was 21 days) is presented here as Cmax.

    Time frame: Day 8 of Cycle 1 (Each cycle was 21 days.)

  15. Extension Period: Change From Baseline in 6MWD (Delayed-Start Analysis)

    6MWD is measured by an exercise test known as 6MWT that assesses aerobic capacity and endurance. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in performance capacity. Each participant's 6MWD was measured at baseline and the timepoint at which the third RCH was performed. This occurred between Month 18 and Month 24, at which time each participant's 6MWD was also measured. An increase in the distance walked during the 6MWT indicates improvement in basic mobility.

    Time frame: Baseline and the timepoint at which third right heart catheterization was performed, which occurred between Month 18 and Month 24

  16. Extension Period: Change From Baseline in 6MWD (Placebo-Crossed Analysis)

    6MWD is measured by an exercise test known as 6MWT that assesses aerobic capacity and endurance. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in performance capacity. Each participant's 6MWD was measured at baseline and the timepoint at which the third right heart catheterization was performed. This occurred between Month 18 and Month 24, at which time each participant's 6MWD was also measured. An increase in the distance walked during the 6MWT indicates improvement in basic mobility.

    Time frame: Baseline and timepoint at which third right heart catheterization was performed, which occurred between Month 18 and Month 24

  17. Extension Period: Number of Participants Who Experienced an Improvement From Baseline in WHO Functional Class (Delayed-Start Analysis)

    The WHO Functional Class describes the severity of a person's pulmonary hypertension symptoms. There are four different classes: I is the mildest and IV the most severe form of pulmonary hypertension. Each participant's WHO Functional Class was assessed at baseline and the timepoint at which the third right heart catheterization was performed. This occurred between Month 18 and Month 24, at which time each participant's WHO Functional Class was also assessed.

    Time frame: Baseline and timepoint at which third right heart catheterization was performed, which occurred between Month 18 and Month 24

  18. Extension Period: Change From Baseline in WHO Functional Class (Placebo-Crossed Analysis)

    The WHO Functional Class describes the severity of a person's pulmonary hypertension symptoms. There are four different classes: I is the mildest and IV the most severe form of pulmonary hypertension. Each participant's WHO Functional Class was assessed at baseline and the timepoint at which the third right heart catheterization was performed. This occurred between Month 18 and Month 24, at which time each participant's WHO Functional Class was also assessed.

    Time frame: Baseline and timepoint at which third right heart catheterization was performed, which occurred between Month 18 and Month 24

07

Results

Posted Apr 19, 2023

Participant flow

Base Study
Participant flow — Base Study
MilestoneExtension Period: Placebo→Sotatercept 0.3 mg/kgExtension Period: Placebo→Sotatercept 0.7 mg/kgPlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kg
Started00323242
Completed00303136
Not completed00216
Withdrew: Adverse event00114
Withdrew: Death00001
Withdrew: Withdrawal by subject00101
Extension Period
Participant flow — Extension Period
MilestoneExtension Period: Placebo→Sotatercept 0.3 mg/kgExtension Period: Placebo→Sotatercept 0.7 mg/kgPlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kg
Started151503136
Completed131502831
Not completed20035
Withdrew: Adverse event00011
Withdrew: Death10012
Withdrew: Withdrawal by subject10011
Withdrew: Elevated hemoglobin levels00001

Outcome measures

PrimaryBase Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks

Each participant's PVR, at resting supine, was measured by right heart catheterization at baseline and at 24 weeks.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · dynes*sec/cm^5
Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks
dynes*sec/cm^5PlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kg
Base Study: Change from Baseline in PVR at 24 Weeks-27.6 ± 251.08-168.4 ± 262.93-258.9 ± 169.42
Baseline802.0 ± 331.05772.0 ± 285.62715.5 ± 267.11
Statistical analysis
  • Placebo vs Sotatercept 0.3 mg/kg · ANCOVA · p = 0.0030 · Difference in least squares means: -151.1 · 95% CI -249.59 to -52.63ANCOVA was used to compare change from baseline values with randomization stratification factor (WHO functional class) and baseline PVR as covariate.
  • Placebo vs Sotatercept 0.7 mg/kg · ANCOVA · p = <.0001 · Difference in least squares means: -269.4 · 95% CI -365.81 to -173.03ANCOVA was used to compare change from baseline values with randomization stratification factor (WHO functional class) and baseline PVR as covariate.
PrimaryExtension Period: Change From Baseline in PVR (Delayed-Start Analysis)

Each participant's PVR, at resting supine, was measured by right heart catheterization at baseline and the timepoint at which the third right heart catheterization was performed, which occurred between Month 18 and Month 24.

Time frame:
Baseline and timepoint at which third right heart catheterization was performed, which occurred between Month 18 and Month 24
Reported as:
Mean · dynes*sec/cm^5
Extension Period: Change From Baseline in PVR (Delayed-Start Analysis)
dynes*sec/cm^5Placebo-Crossed Treatment GroupContinued Sotatercept Treatment Group
Extension Period: Change from Baseline in PVR (Delayed-Start Analysis)-246.9 ± 300.01-212.6 ± 254.24
Baseline802.0 ± 331.05783.7 ± 371.59
Statistical analysis
  • Placebo-Crossed Treatment Group vs Continued Sotatercept Treatment Group · ANCOVA · p = 0.7851 · Difference in least squares means: -13.9 · 95% CI -113.85 to 86.06ANCOVA was used to compare change from baseline values with randomization stratification factor (WHO functional class) and baseline PVR as covariate.
PrimaryExtension Period: Change From Baseline in PVR (Placebo-Crossed Analysis)

Each participant's PVR, at resting supine, was measured by right heart catheterization at baseline and the timepoint at which the third right heart catheterization was performed, which occurred between Month 18 and Month 24.

Time frame:
Baseline and the timepoint at which the third right heart catheterization was performed, which occurred between Month 18 and Month 24.
Reported as:
Mean · dynes*sec/cm^5
Extension Period: Change From Baseline in PVR (Placebo-Crossed Analysis)
dynes*sec/cm^5Placebo-Crossed Treatment Group
Extension Period: Change from Baseline in PVR (Placebo-Crossed Analysis)-246.9 ± 300.01
Baseline802.0 ± 331.05
Statistical analysis
  • Placebo-Crossed Treatment Group · ANCOVA · p = <.0001 (Comparison of baseline and final value) · Multiple imputation mean difference: -223.2 · 95% CI -335.83 to -110.49Standard multiple imputations are done with imputed values that are within the range of the minimum and maximum observed values using linear regression including baseline measurements.
PrimaryExtension Period: Number of Participants Who Experienced One or More Adverse Events (AEs)

An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

Time frame:
Up to approximately 32 months
Reported as:
Count of participants · Participants
Extension Period: Number of Participants Who Experienced One or More Adverse Events (AEs)
ParticipantsExtension Period: Placebo→Sotatercept 0.3 mg/kgExtension Period: Placebo→Sotatercept 0.7 mg/kgExtension Period: Sotatercept 0.3 mg/kgExtension Period: Sotatercept 0.7 mg/kg
Extension Period: Number of Participants Who Experienced One or More Adverse Events (AEs)14153136
PrimaryExtension Period: Number of Participants Who Discontinued Study Treatment Due to an AE

An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

Time frame:
Up to 30 months
Reported as:
Count of participants · Participants
Extension Period: Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsExtension Period: Placebo→Sotatercept 0.3 mg/kgExtension Period: Placebo→Sotatercept 0.7 mg/kgExtension Period: Sotatercept 0.3 mg/kgExtension Period: Sotatercept 0.7 mg/kg
Extension Period: Number of Participants Who Discontinued Study Treatment Due to an AE1013
SecondaryBase Study: Change From Baseline in 6-Minute Walk Distance (6MWD) at 24 Weeks

6MWD is measured by an exercise test known as 6-Minute Walk Test (6MWT) that assesses aerobic capacity and endurance. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in performance capacity. Each participant's 6MWD was measured at baseline and at 24 weeks. An increase in the distance walked during the 6MWT indicates improvement in basic mobility.

Time frame:
Baseline and 24 weeks
Reported as:
Least squares mean · meters
Base Study: Change From Baseline in 6-Minute Walk Distance (6MWD) at 24 Weeks
metersPlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kg
Base Study: Change From Baseline in 6-Minute Walk Distance (6MWD) at 24 Weeks31.4 ± 9.6956.0 ± 10.0753.6 ± 9.84
SecondaryBase Study: Change From Baseline in Concentration of Amino-Terminal Brain Natriuretic Propeptide (NT-proBNP) at 24 Weeks

Each participant's laboratory biomarkers N-terminal prohormone brain-type natriuretic peptide (NT-proBNP) or brain-type natriuretic peptide (BNP) were measured at baseline and at 24 weeks.

Time frame:
Baseline and 24 Weeks
Reported as:
Mean · pg/mL
Base Study: Change From Baseline in Concentration of Amino-Terminal Brain Natriuretic Propeptide (NT-proBNP) at 24 Weeks
pg/mLPlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kg
Base Study: Change From Baseline in Concentration of Amino-Terminal Brain Natriuretic Propeptide (NT-proBNP) at 24 Weeks195.9 ± 726.46-718.2 ± 965.12-359.0 ± 757.58
SecondaryBase Study: Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE) at 24 Weeks

Each participant's TAPSE, which is commonly used to evaluate tricuspid valve annulus movement as an indicator of right heart function, was measured by echocardiography at baseline and 24 weeks.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · cm
Base Study: Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE) at 24 Weeks
cmPlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kg
Base Study: Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE) at 24 Weeks0.0 ± 0.390.1 ± 0.26-0.1 ± 0.34
SecondaryBase Study: Change From Baseline in Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) Score at Cycle 9

The CAMPHOR is participant-reported questionnaire that contains 65 items in total, 25 relating to symptoms, 25 relating to quality of life (QoL), and 15 relating to activities. Symptom items are scored from 0-25, with a higher score indicating worse symptoms. QoL items are also scored from 0-25, with a higher score indicating a worse QoL and greater functional limitation. Activity items are scored from 0-30, with a higher score indicating poorer functioning. The combined score is obtained by summing up the symptoms score, QoL score and activity score. The lowest combined score possible is 0, while the highest combined score possible is 80. Each participant's CAMPHOR score was recorded at baseline and on Day 1 of Cycle 9.

Time frame:
Baseline and Day 1 of Cycle 9, up to 24 weeks (Each cycle was 21 days.)
Reported as:
Mean · Score on a scale
Base Study: Change From Baseline in Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) Score at Cycle 9
Score on a scalePlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kg
Base Study: Change From Baseline in Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) Score at Cycle 9-10.2 ± 12.91-6.9 ± 12.51-7.5 ± 7.96
SecondaryBase Study: Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score

The SF-36 questionnaire is a participant-reported survey of a participant's health. The survey evaluates 8 aspects of functional health and well-being that relate to either physical health or mental health. The physical component summary is based primarily on physical functioning, bodily pain, and general health. The mental component summary encompasses vitality, social functioning, and emotional and mental health. Total scores for the physical component range from 0-100, with 100 representing the highest level of physical functioning. The total scores for the mental component also range from 0-100, with 100 representing the highest level of mental functioning. Each participant's SF-36 was recorded at baseline and on Day 1 of Cycle 9. Each cycle was 21 days.

Time frame:
Baseline and Day 1 of Cycle 9, up to 24 weeks (Each cycle was 21 days.)
Reported as:
Least squares mean · Score on a scale
Base Study: Change From Baseline in 36-Item Short Form Health Survey (SF-36) Score
Score on a scalePlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kg
Physical component3.5 ± 1.074.5 ± 1.123.1 ± 1.11
Mental component3.2 ± 1.333.6 ± 1.390.0 ± 1.40
SecondaryBase Study: Number of Participants Who Experienced Events Indicative of Clinical Worsening of Pulmonary Arterial Hypertension (PAH)

Events that indicate clinical worsening of PAH include death, need for and/or worsening-related listing for lung and/or heart transplant, need to initiate an approved PAH SOC rescue therapy, PAH-specific hospitalization, or functional deterioration (worsened WHO Functional Class AND 15% decrease in 6MWD).

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Base Study: Number of Participants Who Experienced Events Indicative of Clinical Worsening of Pulmonary Arterial Hypertension (PAH)
ParticipantsPlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kg
Base Study: Number of Participants Who Experienced Events Indicative of Clinical Worsening of Pulmonary Arterial Hypertension (PAH)201
SecondaryBase Study: Number of Participants Who Experienced an Improvement From Baseline in World Health Organization (WHO) Functional Class at 24 Weeks

The WHO Functional Class describes the severity of a person's pulmonary hypertension symptoms. There are four different classes: I is the mildest and IV the most severe form of pulmonary hypertension.

Time frame:
Baseline and 24 Weeks
Reported as:
Count of participants · Participants
Base Study: Number of Participants Who Experienced an Improvement From Baseline in World Health Organization (WHO) Functional Class at 24 Weeks
ParticipantsPlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kg
Base Study: Number of Participants Who Experienced an Improvement From Baseline in World Health Organization (WHO) Functional Class at 24 Weeks486
SecondaryBase Study: Number of Participants Who Experienced One or More AEs

An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Base Study: Number of Participants Who Experienced One or More AEs
ParticipantsPlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kg
Base Study: Number of Participants Who Experienced One or More AEs292935
SecondaryBase Study: Number of Participants Who Discontinued Study Treatment Due to an AE

An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Base Study: Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsPlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kg
Base Study: Number of Participants Who Discontinued Study Treatment Due to an AE115
SecondaryBase Study: Change From Baseline in Body Mass Index (BMI) at Cycle 9

Each participant's BMI was measured at baseline and at 24 weeks.

Time frame:
Baseline and Day 1 of Cycle 9, up to 24 weeks (Each cycle was 21 days.)
Reported as:
Mean · kg/m^2
Base Study: Change From Baseline in Body Mass Index (BMI) at Cycle 9
kg/m^2PlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kg
Base Study: Change From Baseline in Body Mass Index (BMI) at Cycle 9-0.2 ± 1.250.6 ± 0.890.2 ± 1.07
SecondaryBase Study: Change From Baseline in Systolic and Diastolic Blood Pressure at Cycle 9

Each participant's systolic and diastolic blood pressure was taken at baseline and on Day 1 of Cycle 9. Each cycle was 21 days.

Time frame:
Baseline and Day 1 of Cycle 9, up to 24 weeks (Each cycle was 21 days.)
Reported as:
Mean · mmHg
Base Study: Change From Baseline in Systolic and Diastolic Blood Pressure at Cycle 9
mmHgPlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kg
Systolic blood pressure-0.8 ± 10.063.4 ± 11.752.6 ± 12.28
Diastolic blood pressure2.3 ± 8.064.1 ± 8.641.7 ± 8.69
SecondaryBase Study: Change From Baseline in Respiratory Rate at Cycle 9

Each participant's respiratory rate (number of breaths per minute) was measured at baseline and on Day 1 of Cycle 9. Each cycle was 21 days.

Time frame:
Baseline and Day 1 of Cycle 9, up to 24 weeks (Each cycle was 21 days.)
Reported as:
Mean · breaths/min
Base Study: Change From Baseline in Respiratory Rate at Cycle 9
breaths/minPlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kg
Base Study: Change From Baseline in Respiratory Rate at Cycle 9-0.3 ± 2.10-1.3 ± 3.72-0.3 ± 3.05
SecondaryBase Study: Change From Baseline in QTcF Interval at Cycle 9

Each participant's QTcF Interval was measured at baseline and on Day 1 of Cycle 9.

Time frame:
Baseline and Day 1 of Cycle 9, up to 24 weeks (Each cycle was 21 days.)
Reported as:
Mean · milliseconds
Base Study: Change From Baseline in QTcF Interval at Cycle 9
millisecondsPlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kg
Base Study: Change From Baseline in QTcF Interval at Cycle 90.7 ± 31.10-7.4 ± 20.57-9.1 ± 31.55
SecondaryBase Study: Maximum Plasma Concentration (Cmax) of Sotatercept

Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Based on population pharmacokinetic (PopPK) modeling of previous sotatercept studies, Cmax occurs at Day 8 of Cycle 1 after a sotatercept dose is given. The sotatercept concentration at Day 8 of Cycle 1 (each cycle was 21 days) is presented here as Cmax.

Time frame:
Day 8 of Cycle 1 (Each cycle was 21 days.)
Reported as:
Mean · ng/mL
Base Study: Maximum Plasma Concentration (Cmax) of Sotatercept
ng/mLSotatercept 0.3 mg/kgSotatercept 0.7 mg/kg
Base Study: Maximum Plasma Concentration (Cmax) of Sotatercept1910.3 ± 715.864598.5 ± 1622.59
SecondaryExtension Period: Change From Baseline in 6MWD (Delayed-Start Analysis)

6MWD is measured by an exercise test known as 6MWT that assesses aerobic capacity and endurance. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in performance capacity. Each participant's 6MWD was measured at baseline and the timepoint at which the third RCH was performed. This occurred between Month 18 and Month 24, at which time each participant's 6MWD was also measured. An increase in the distance walked during the 6MWT indicates improvement in basic mobility.

Time frame:
Baseline and the timepoint at which third right heart catheterization was performed, which occurred between Month 18 and Month 24
Reported as:
Least squares mean · meters
Extension Period: Change From Baseline in 6MWD (Delayed-Start Analysis)
metersPlacebo-Crossed Treatment GroupContinued Sotatercept Treatment Group
Extension Period: Change From Baseline in 6MWD (Delayed-Start Analysis)60.1 ± 14.3555.7 ± 9.47
SecondaryExtension Period: Change From Baseline in 6MWD (Placebo-Crossed Analysis)

6MWD is measured by an exercise test known as 6MWT that assesses aerobic capacity and endurance. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in performance capacity. Each participant's 6MWD was measured at baseline and the timepoint at which the third right heart catheterization was performed. This occurred between Month 18 and Month 24, at which time each participant's 6MWD was also measured. An increase in the distance walked during the 6MWT indicates improvement in basic mobility.

Time frame:
Baseline and timepoint at which third right heart catheterization was performed, which occurred between Month 18 and Month 24
Reported as:
Mean · meters
Extension Period: Change From Baseline in 6MWD (Placebo-Crossed Analysis)
metersPlacebo-Crossed Treatment Group
Extension Period: Change From Baseline in 6MWD (Placebo-Crossed Analysis)60.5 ± 13.21
SecondaryExtension Period: Number of Participants Who Experienced an Improvement From Baseline in WHO Functional Class (Delayed-Start Analysis)

The WHO Functional Class describes the severity of a person's pulmonary hypertension symptoms. There are four different classes: I is the mildest and IV the most severe form of pulmonary hypertension. Each participant's WHO Functional Class was assessed at baseline and the timepoint at which the third right heart catheterization was performed. This occurred between Month 18 and Month 24, at which time each participant's WHO Functional Class was also assessed.

Time frame:
Baseline and timepoint at which third right heart catheterization was performed, which occurred between Month 18 and Month 24
Reported as:
Count of participants · Participants
Extension Period: Number of Participants Who Experienced an Improvement From Baseline in WHO Functional Class (Delayed-Start Analysis)
ParticipantsPlacebo-Crossed Treatment GroupContinued Sotatercept Treatment Group
Extension Period: Number of Participants Who Experienced an Improvement From Baseline in WHO Functional Class (Delayed-Start Analysis)1627
SecondaryExtension Period: Change From Baseline in WHO Functional Class (Placebo-Crossed Analysis)

The WHO Functional Class describes the severity of a person's pulmonary hypertension symptoms. There are four different classes: I is the mildest and IV the most severe form of pulmonary hypertension. Each participant's WHO Functional Class was assessed at baseline and the timepoint at which the third right heart catheterization was performed. This occurred between Month 18 and Month 24, at which time each participant's WHO Functional Class was also assessed.

Time frame:
Baseline and timepoint at which third right heart catheterization was performed, which occurred between Month 18 and Month 24
Reported as:
Mean · WHO functional class
Extension Period: Change From Baseline in WHO Functional Class (Placebo-Crossed Analysis)
WHO functional classPlacebo-Crossed Treatment Group
Extension Period: Change From Baseline in WHO Functional Class (Placebo-Crossed Analysis)-0.6 ± 0.74

Adverse events

Collected over Treatment period: Up to 24 weeks; Extension period: Up to approximately 32 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Base Study: Placebo0/32 (0%)3/32 (9.4%)25/32 (78.1%)
Base Study: Sotatercept 0.3 mg/kg0/32 (0%)2/32 (6.3%)29/32 (90.6%)
Base Study: Sotatercept 0.7 mg/kg1/42 (2.4%)10/42 (23.8%)33/42 (78.6%)
Extension Period: Placebo→Sotatercept 0.3 mg/kg1/15 (6.7%)6/15 (40%)14/15 (93.3%)
Extension Period: Placebo→Sotatercept 0.7 mg/kg0/15 (0%)4/15 (26.7%)15/15 (100%)
Extension Period: Sotatercept 0.3 mg/kg1/32 (3.1%)10/31 (32.3%)30/31 (96.8%)
Extension Period: Sotatercept 0.7 mg/kg2/42 (4.8%)12/36 (33.3%)36/36 (100%)
Most frequent serious events
Showing 10 of 66
Most frequent serious events
EventBase Study: PlaceboBase Study: Sotatercept 0.3 mg/kgBase Study: Sotatercept 0.7 mg/kgExtension Period: Placebo→Sotatercept 0.3 mg/kgExtension Period: Placebo→Sotatercept 0.7 mg/kgExtension Period: Sotatercept 0.3 mg/kgExtension Period: Sotatercept 0.7 mg/kg
Device malfunctionProduct Issues0/320/320/422/150/150/312/36
PneumoniaInfections and infestations0/320/320/421/150/151/313/36
Tachycardia paroxysmalCardiac disorders0/320/320/421/150/150/310/36
BronchitisInfections and infestations0/320/321/421/150/150/310/36
Gastrointestinal infectionInfections and infestations0/320/320/421/150/150/310/36
PyelonephritisInfections and infestations0/320/320/420/151/150/310/36
Respiratory tract infectionInfections and infestations0/320/321/421/150/150/310/36
Ankle fractureInjury, poisoning and procedural complications0/320/320/420/151/150/310/36
Colon neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/320/320/421/150/150/310/36
Ischaemic strokeNervous system disorders0/320/320/421/150/150/310/36
Most frequent other events
Showing 10 of 223
Most frequent other events
EventBase Study: PlaceboBase Study: Sotatercept 0.3 mg/kgBase Study: Sotatercept 0.7 mg/kgExtension Period: Placebo→Sotatercept 0.3 mg/kgExtension Period: Placebo→Sotatercept 0.7 mg/kgExtension Period: Sotatercept 0.3 mg/kgExtension Period: Sotatercept 0.7 mg/kg
HeadacheNervous system disorders6/328/326/424/157/159/316/36
FatigueGeneral disorders6/322/324/426/154/156/315/36
Oedema peripheralGeneral disorders5/323/325/424/156/1511/317/36
NasopharyngitisInfections and infestations3/321/324/425/156/1510/311/36
DiarrhoeaGastrointestinal disorders5/327/326/423/155/159/315/36
Haemoglobin increasedInvestigations0/321/327/421/155/150/315/36
ArthralgiaMusculoskeletal and connective tissue disorders5/322/321/422/155/158/315/36
TelangiectasiaSkin and subcutaneous tissue disorders0/320/320/424/155/155/317/36
NauseaGastrointestinal disorders5/323/325/423/154/159/315/36
Iron deficiency anaemiaBlood and lymphatic system disorders2/321/320/420/154/151/313/36

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kgTotal
Mean45.6 ± 13.3849.1 ± 14.3449.8 ± 15.0548.3 ± 14.33
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kgTotal
Female26293792
Male63514
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kgTotal
Hispanic or Latino1091332
Not Hispanic or Latino21192868
Unknown or Not Reported1416
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboSotatercept 0.3 mg/kgSotatercept 0.7 mg/kgTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander1001
Black or African American0134
White30313798
More than one race1012
Unknown or Not Reported0011
08

Study locations

43 sites
  • Pulmonary Associates, PA
    Phoenix, Arizona 85006, United States
  • Arizona Pulmonary Specialists
    Phoenix, Arizona 85012, United States
  • Banner-University Medical Center Phoenix
    Phoenix, Arizona 85381, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • University of California, San Francisco Medical Center
    San Francisco, California 94143, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • UF Health Shands Hospital
    Gainesville, Florida 32610, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Lindner Clinical Trial Center
    Cincinnati, Ohio 45129, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • St. Vincent's Hospital Sydney
    Darlinghurst, New South Wales 2010, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • John Hunter Hospital
    New Lambton, New South Whales 2305, Australia
  • Prince Charles Hospital
    Chermside, Queensland 4032, Australia
  • Hospital Madre Teresa
    Belo Horizonte, Minas Gerais 30430, Brazil
  • Irmandade Da Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, Riogrande Do Sul 90035, Brazil
  • Hospital Dia do Pulmão
    Blumenau, Santa Catarina 89010, Brazil
  • Instituto do Coracao - HCFMUSP
    Cerqueira César, 05403-900, Brazil
  • Hospital Sao Lucas da PUCRS
    Jardim Botânico, 05403-900, Brazil
  • Hospital São Paulo
    Sao Paulo, 04037, Brazil
  • Hôpital Arnaud de Villeneuve
    Montpellier, Hérault 34295, France
  • CHU Michallon
    La Tronche, 38700, France
  • Centre Hospitalier Universitaire de Bicêtre
    Le Kremlin-Bicêtre, 94275, France
  • Centre Hospitalier Universitaire de Saint Etienne
    Saint-Étienne, 42055, France
  • Medizinische Hochschule Hannover
    Hannover, Niedersachsen 30625, Germany
  • Universitatsklinikum Halle (Saale)
    Halle, Sachsen-Anhalt 06120, Germany
  • Universitatsklinikum Leipzig
    Leipzig, Sachsen 04103, Germany
  • Universitätsklinikum Carl Gustav Carus an der TU Dresden
    Dresden, 01307, Germany
  • Barzilai Medical Center
    Ashkelon, 78278, Israel
  • Lady Davis Carmel Medical Center
    Haifa, 34362, Israel
  • Meir Medical Center
    Kefar Sava, 4428100, Israel
  • Rabin Medical Center - PPDS
    Petach-Tikva, 49100, Israel
  • Chaim Sheba Medical Center
    Ramat Gan, 52621, Israel
  • Hospital Universitario Marques de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital Universitario Puerta de Hierro-Majadahonda
    Majadahonda, Madrid 28222, Spain
  • Hospital Universitario Vall d'Hebron - PPDS
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Golden Jubilee National Hospital - PPDS
    Clydebank, G81 4DY, United Kingdom
  • Royal Free London NHS Foundation Trust
    London, NW32QG, United Kingdom
  • Imperial College Healthcare NHS Trust
    London, W2 1NY, United Kingdom
09

References and documents

Publications

  • Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Ghofrani HA, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, de Oliveira Pena J, Badesch DB. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. Eur Respir J. 2023 Jan 6;61(1):2201347. doi: 10.1183/13993003.01347-2022. Print 2023 Jan. PubMed 36041750 ↗
  • Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman A, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, Barnes J, Linde PG, de Oliveira Pena J, Badesch DB; PULSAR Trial Investigators. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2021 Apr 1;384(13):1204-1215. doi: 10.1056/NEJMoa2024277. PubMed 33789009 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Mar 2022, 44 months.

Results were first posted in Apr 2023, 1 year 1 month after primary completion.

Of 28 industry-sponsored phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's 44 months is above that.

Counting every sponsor, half of 51 studies reached it within 44 months; a quarter within 26 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2018
First posted
Apr 12, 2018
StartActual
Jun 13, 2018
Primary completionActual
Mar 9, 2022
CompletionActual
Mar 9, 2022
Results first posted
Apr 19, 2023
Last update
Apr 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03496207
Responsible party
Sponsor
First posted
Apr 12, 2018
Start date
Jun 13, 2018
Primary completion
Mar 9, 2022
Completion
Mar 9, 2022
Results posted
Apr 19, 2023
Last update
Apr 19, 2023

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion